EGQ0 Stock Overview
Engages in the developing and commercializing of diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
INOVIQ Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.28 |
| 52 Week High | AU$0.41 |
| 52 Week Low | AU$0.25 |
| Beta | 2.04 |
| 11 Month Change | -4.14% |
| 3 Month Change | -17.26% |
| 1 Year Change | n/a |
| 33 Year Change | -57.88% |
| 5 Year Change | -45.49% |
| Change since IPO | -7.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| EGQ0 | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | 6.9% | 0.8% | -0.2% |
| 1Y | n/a | 17.2% | 7.8% |
Return vs Industry: Insufficient data to determine how EGQ0 performed against the German Healthcare industry.
Return vs Market: Insufficient data to determine how EGQ0 performed against the German Market.
Price Volatility
| EGQ0 volatility | |
|---|---|
| EGQ0 Average Weekly Movement | 5.3% |
| Healthcare Industry Average Movement | 4.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: EGQ0 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine EGQ0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | Leearne Hinch | www.inoviq.com |
INOVIQ Ltd engages in the developing and commercializing of diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. The company offers hTERT test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an EV isolation tool for biomarker discovery and diagnostic development. Its cancer diagnostic pipeline includes internal and partnered diagnostic tests for improved screening, diagnosis, treatment selection and monitoring of cancer and other diseases.
INOVIQ Ltd Fundamentals Summary
| EGQ0 fundamental statistics | |
|---|---|
| Market cap | €32.31m |
| Earnings (TTM) | -€4.04m |
| Revenue (TTM) | €962.58k |
33.6x
P/S Ratio-8.0x
P/E RatioIs EGQ0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EGQ0 income statement (TTM) | |
|---|---|
| Revenue | AU$1.56m |
| Cost of Revenue | AU$2.78m |
| Gross Profit | -AU$1.22m |
| Other Expenses | AU$5.34m |
| Earnings | -AU$6.55m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.059 |
| Gross Margin | -78.07% |
| Net Profit Margin | -419.73% |
| Debt/Equity Ratio | 0% |
How did EGQ0 perform over the long term?
See historical performance and comparison